ADAPY Adaptimmune Therapeutics PLC
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1621227 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-54.0%
TTM net income YoY-134.1%
TTM EPS YoY-83.3%
Revenue 3-yr CAGR77.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-252.3%
Net margin-260.8%
FCF margin-294.5%
EBITDA margin-237.0%
Returns
ROE-1,341.1%
ROA-75.1%
ROIC (approx.)—
Asset turnover0.29x
Leverage & solvency
Liabilities / assets154.3%
Debt / equity—
Current ratio1.52x
Interest coverage-28.99x
Cash quality & payout
Operating cash flow / net income1.12x
Accruals ratio9.0%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 | 2023Q4*2023-12-31 | 2023Q32023-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $13.68M | $7.29M | $3.22M | $40.90M | $128.23M | $5.68M | $231,000 | $7.32M |
| Cost of revenue | $2.50M | $879,000 | — | — | — | — | — | — |
| Gross profit | $11.18M | $6.41M | — | — | — | — | — | — |
| R&D expense | $22.98M | $28.86M | $39.10M | $34.30M | $40.45M | $35.21M | $33.21M | $37.79M |
| SG&A expense | $18.48M | $23.28M | $27.17M | $21.28M | $19.08M | $19.73M | $16.88M | $16.16M |
| Operating income | -$30.29M | -$45.73M | -$73.52M | -$14.68M | $68.70M | -$49.26M | -$49.86M | -$46.63M |
| Interest expense | $962,000 | $1.88M | $1.71M | $1.11M | $526,000 | — | — | — |
| Pretax income | -$29.73M | -$47.01M | -$72.52M | -$16.79M | $70.05M | -$47.98M | -$48.57M | -$44.91M |
| Income tax | $612,000 | $575,000 | $1.69M | $831,000 | $526,000 | $526,000 | -$656,000 | $687,000 |
| Net income | -$30.34M | -$47.58M | -$74.22M | -$17.62M | $69.52M | -$48.50M | -$47.92M | -$45.60M |
| EBITDA | -$27.96M | -$43.44M | -$70.86M | -$11.98M | $71.39M | -$46.49M | -$47.05M | -$43.81M |
| EPS (basic) | -0.02 | -0.03 | — | -0.01 | 0.05 | -0.03 | — | -0.03 |
| EPS (diluted) | -0.02 | -0.03 | — | -0.01 | 0.04 | -0.03 | — | -0.03 |
| Weighted avg. shares (diluted) | 1.58B | 1.54B | — | 1.53B | 1.56B | 1.45B | — | 1.36B |
| Balance sheet | ||||||||
| Cash & equivalents | $26.06M | $41.05M | $91.14M | $116.74M | $214.68M | $143.53M | $147.02M | $93.07M |
| Short-term investments | $0 | $18.51M | $60.47M | $69.35M | $2.98M | $2.98M | $2.95M | $71.67M |
| Receivables | $9.31M | $4.38M | $1.45M | $12.50M | $2.33M | $8.40M | $821,000 | $789,000 |
| Inventory | $11.41M | $11.76M | $7.32M | $1.87M | — | — | — | — |
| Current assets | $78.11M | $103.00M | $188.17M | $244.21M | $253.77M | $186.90M | $207.55M | $219.37M |
| PP&E, net | $28.15M | $29.72M | $31.31M | $44.80M | $45.87M | $48.29M | $50.95M | $52.57M |
| Intangibles | $3.81M | $3.81M | $3.88M | $4.28M | $996,000 | $524,000 | $330,000 | $384,000 |
| Total assets | $130.63M | $158.07M | $245.96M | $317.44M | $321.70M | $258.01M | $282.62M | $296.64M |
| Current liabilities | $51.51M | $51.07M | $64.53M | $63.46M | $82.07M | $66.41M | $72.79M | $75.15M |
| Long-term debt | $25.68M | $25.41M | $50.24M | $49.87M | $24.95M | — | — | — |
| Total debt | $25.68M | $25.41M | $50.24M | $49.87M | $24.95M | — | — | — |
| Total liabilities | $201.59M | $195.50M | $234.11M | $237.45M | $225.43M | $233.63M | $243.10M | $208.51M |
| Shareholders' equity | -$70.96M | -$37.43M | $11.85M | $79.99M | $96.27M | $24.38M | $39.51M | $88.13M |
| Net debt | -$386,000 | -$15.64M | -$40.90M | -$66.88M | -$189.72M | — | — | — |
| Shares outstanding | 1.59B | 1.55B | 1.54B | 1.53B | 1.53B | 1.53B | 1.36B | 1.36B |
| Cash flow statement | ||||||||
| Operating cash flow | -$34.78M | -$66.59M | -$34.20M | -$54.45M | $47.40M | -$31.95M | -$14.68M | -$45.16M |
| Capital expenditure | $75,000 | $1.20M | $219,000 | $143,000 | $422,000 | $102,000 | $827,000 | $289,000 |
| Free cash flow | -$34.85M | -$67.80M | -$34.42M | -$54.59M | $46.98M | -$32.05M | -$15.50M | -$45.45M |
| Investing cash flow | $18.49M | $41.15M | $8.17M | -$66.02M | -$743,000 | -$358,000 | $68.20M | $57.31M |
| Financing cash flow | $1.65M | -$25.32M | $1,000 | $25.00M | $24.51M | $29.23M | $74,000 | $596,000 |
| Depreciation & amortization | $2.33M | $2.29M | $2.66M | $2.70M | $2.69M | $2.77M | $2.81M | $2.82M |
| Stock-based compensation | $1.32M | $669,000 | $2.84M | $3.05M | $3.06M | $3.10M | $3.08M | $3.18M |
Free plan shows the latest 8 periods; Pro shows all 42 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.